Vaccinex Inc
VCNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.68M
Close$
$7.27
840.7% upside
Current Fair Value
840.7% upsideUndervalued by 840.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.68 Million |
|---|---|
| Enterprise Value | $1.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.88 |
| Beta | 0.56 |
| Outstanding Shares | 2,098,947 |
Return
| Return on Equity | 748.95% |
|---|---|
| Return on Assets | -717.80% |
| Return on Invested Capital | 754.50% |
Valuation & Multiples
| P/E Ratio | -0.11 |
|---|---|
| PEG | -6.55 |
| Price to Sales | - |
| Price to Book Ratio | -0.39 |
| Enterprise Value to Revenue | 2.65 |
| Enterprise Value to EBIT | -0.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-73.04
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-73.04
Average shareholder expectationRevenue Estimate
$50,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $17 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Vaccinex Inc
40 employeesVaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a ...